Literature DB >> 19326031

SV40-transformed human corneal keratocytes: optimisation of serum-free culture conditions.

Anna Katharina Manzer1, Simone Lombardi-Borgia, Monika Schäfer-Korting, Judith Seeber, Michaela Zorn-Kruppa, Maria Engelke.   

Abstract

Aiming at the replacement of animal experiments in eye irritation testing, we have established a multilay ered cornea model comprising the co-culture of all three corneal cell types. It was the objective of this study to optimise serum-free culture conditions to preserve both growth and phenotype of an SV40-immortalised human corneal keratocyte cell line (HCK). Our results revealed that HCK continue to proliferate in both monolayer cultures as well as after seeding in a collagen matrix and resemble primary corneal keratocytes in morphology and functional characteristics under defined serum-free conditions. Furthermore, HCK were shown to transform into activated corneal fibroblast phenotypes in response to serum and TGF(beta)1. In summary, HCK cells mimic their in vivo (primary) precursors, both in sustaining the quiescent keratocyte phenotype (serum-starved conditions) and in responding to growth factor stimulation. Hence, this cell line may provide a useful tool to study the toxicity and wound healing response of corneal keratocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326031     DOI: 10.14573/altex.2009.1.33

Source DB:  PubMed          Journal:  ALTEX        ISSN: 1868-596X            Impact factor:   6.043


  2 in total

1.  Myofibroblast transdifferentiation of keratocytes results in slower migration and lower sensitivity to mesoscale curvatures.

Authors:  Cas van der Putten; Daniëlle van den Broek; Nicholas A Kurniawan
Journal:  Front Cell Dev Biol       Date:  2022-07-22

2.  Determining the Depth of Injury in Bioengineered Tissue Models of Cornea and Conjunctiva for the Prediction of All Three Ocular GHS Categories.

Authors:  Michaela Zorn-Kruppa; Pia Houdek; Ewa Wladykowski; Maria Engelke; Melinda Bartok; Karsten R Mewes; Ingrid Moll; Johanna M Brandner
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.